|Bid||2.7900 x 2200|
|Ask||2.8000 x 4000|
|Day's Range||2.7100 - 2.8100|
|52 Week Range||1.8300 - 18.4400|
|Beta (5Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2023 - Feb 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.84|
Subscribe to Yahoo Finance Plus to view Fair Value for NVTA
Shares of medical genetics testing company Invitae (NYSE: NVTA) rose 11% on Tuesday. Invitate didn't have any announcements on Tuesday, though it is presenting research this week in Nashville, Tennessee, at the National Society of Genetic Counselors conference. Invitae reported revenue of $133.5 million, up 16.7%, year over year.
Two stocks that could climb fivefold if they make progress toward their goals are Teladoc Health (NYSE: TDOC) and Invitae (NYSE: NVTA). Teladoc and Invitae shares both have lost more than 70% this year. Teladoc disappointed investors with two massive noncash goodwill impairment charges linked to an acquisition.
Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are presenting research next week at the National Society of Genetic Counselors (NSGC) 41st Annual Conference in Nashville enabling the progress of the science and practice of genetics in patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award, which recognizes excellence in the field of genetic counseling.